138 related articles for article (PubMed ID: 36197797)
41. Lysyl Oxidase-Like 2 Protects against Progressive and Aging Related Knee Joint Osteoarthritis in Mice.
Tashkandi M; Ali F; Alsaqer S; Alhousami T; Cano A; Martin A; Salvador F; Portillo F; C Gerstenfeld L; Goldring MB; Bais MV
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569601
[TBL] [Abstract][Full Text] [Related]
42. SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma.
Zhu Y; Zhu MX; Zhang XD; Xu XE; Wu ZY; Liao LD; Li LY; Xie YM; Wu JY; Zou HY; Xie JJ; Li EM; Xu LY
Hum Pathol; 2016 Jun; 52():153-63. PubMed ID: 26980013
[TBL] [Abstract][Full Text] [Related]
43. Linking LOXL2 to Cardiac Interstitial Fibrosis.
Erasmus M; Samodien E; Lecour S; Cour M; Lorenzo O; Dludla P; Pheiffer C; Johnson R
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824630
[TBL] [Abstract][Full Text] [Related]
44. 67 laminin receptor promotes the malignant potential of tumour cells up-regulating lysyl oxidase-like 2 expression in cholangiocarcinoma.
Xu J; Li D; Li X; Liu Z; Li T; Jiang P; He Q; Tian F; Gao Y; Wang D; Wang S
Dig Liver Dis; 2014 Aug; 46(8):750-7. PubMed ID: 24794791
[TBL] [Abstract][Full Text] [Related]
45. Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.
Chang J; Lucas MC; Leonte LE; Garcia-Montolio M; Singh LB; Findlay AD; Deodhar M; Foot JS; Jarolimek W; Timpson P; Erler JT; Cox TR
Oncotarget; 2017 Apr; 8(16):26066-26078. PubMed ID: 28199967
[TBL] [Abstract][Full Text] [Related]
46. Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor.
Rodriguez HM; Vaysberg M; Mikels A; McCauley S; Velayo AC; Garcia C; Smith V
J Biol Chem; 2010 Jul; 285(27):20964-74. PubMed ID: 20439985
[TBL] [Abstract][Full Text] [Related]
47. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.
Moon HJ; Finney J; Xu L; Moore D; Welch DR; Mure M
J Biol Chem; 2013 Oct; 288(42):30000-30008. PubMed ID: 24014025
[TBL] [Abstract][Full Text] [Related]
48. Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice.
Cosgrove D; Dufek B; Meehan DT; Delimont D; Hartnett M; Samuelson G; Gratton MA; Phillips G; MacKenna DA; Bain G
Kidney Int; 2018 Aug; 94(2):303-314. PubMed ID: 29759420
[TBL] [Abstract][Full Text] [Related]
49. LOXL2 in Cancer: A Two-Decade Perspective.
Cano A; Eraso P; Mazón MJ; Portillo F
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762708
[TBL] [Abstract][Full Text] [Related]
50. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.
Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS
Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063
[TBL] [Abstract][Full Text] [Related]
51. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway.
Hong X; Yu JJ
Int J Oncol; 2019 May; 54(5):1676-1690. PubMed ID: 30816490
[TBL] [Abstract][Full Text] [Related]
52. A novel splice variant of LOXL2 promotes progression of human papillomavirus-negative head and neck squamous cell carcinoma.
Liu C; Guo T; Sakai A; Ren S; Fukusumi T; Ando M; Sadat S; Saito Y; Califano JA
Cancer; 2020 Feb; 126(4):737-748. PubMed ID: 31721164
[TBL] [Abstract][Full Text] [Related]
53. Functional analysis of LOXL2 in pancreatic carcinoma.
Rückert F; Joensson P; Saeger HD; Grützmann R; Pilarsky C
Int J Colorectal Dis; 2010 Mar; 25(3):303-11. PubMed ID: 20012301
[TBL] [Abstract][Full Text] [Related]
54. Reciprocal regulation of LOX and LOXL2 expression during cell adhesion and terminal differentiation in epidermal keratinocytes.
Fujimoto E; Tajima S
J Dermatol Sci; 2009 Aug; 55(2):91-8. PubMed ID: 19394199
[TBL] [Abstract][Full Text] [Related]
55. LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells.
Cebrià-Costa JP; Pascual-Reguant L; Gonzalez-Perez A; Serra-Bardenys G; Querol J; Cosín M; Verde G; Cigliano RA; Sanseverino W; Segura-Bayona S; Iturbide A; Andreu D; Nuciforo P; Bernado-Morales C; Rodilla V; Arribas J; Yelamos J; de Herreros AG; Stracker TH; Peiró S
Oncogene; 2020 Jan; 39(1):79-121. PubMed ID: 31462706
[TBL] [Abstract][Full Text] [Related]
56. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution.
Barker HE; Chang J; Cox TR; Lang G; Bird D; Nicolau M; Evans HR; Gartland A; Erler JT
Cancer Res; 2011 Mar; 71(5):1561-72. PubMed ID: 21233336
[TBL] [Abstract][Full Text] [Related]
57. LOXL2 status correlates with tumor stage and regulates integrin levels to promote tumor progression in ccRCC.
Hase H; Jingushi K; Ueda Y; Kitae K; Egawa H; Ohshio I; Kawakami R; Kashiwagi Y; Tsukada Y; Kobayashi T; Nakata W; Fujita K; Uemura M; Nonomura N; Tsujikawa K
Mol Cancer Res; 2014 Dec; 12(12):1807-17. PubMed ID: 25092917
[TBL] [Abstract][Full Text] [Related]
58. Tumor-secreted LOXL2 activates fibroblasts through FAK signaling.
Barker HE; Bird D; Lang G; Erler JT
Mol Cancer Res; 2013 Nov; 11(11):1425-36. PubMed ID: 24008674
[TBL] [Abstract][Full Text] [Related]
59. Identification of a novel lysyl oxidase-like 2 alternative splicing isoform, LOXL2 Δe13, in esophageal squamous cell carcinoma.
Lv GQ; Zou HY; Liao LD; Cao HH; Zeng FM; Wu BL; Xie JJ; Fang WK; Xu LY; Li EM
Biochem Cell Biol; 2014 Oct; 92(5):379-89. PubMed ID: 25275797
[TBL] [Abstract][Full Text] [Related]
60. Salidroside ameliorated hypoxia-induced tumorigenesis of BxPC-3 cells via downregulating hypoxia-inducible factor (HIF)-1α and LOXL2.
Chen X; Kou Y; Lu Y; Pu Y
J Cell Biochem; 2020 Jan; 121(1):165-173. PubMed ID: 31162697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
